Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 4 of 26 for:    avanir

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2015 by Avanir Pharmaceuticals.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Avanir Pharmaceuticals Identifier:
First received: May 29, 2014
Last updated: January 28, 2015
Last verified: January 2015
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate response to standard antidepressant treatment. A secondary objective of this study is to assess the pharmacokinetics (PK) of AVP-786 and potential correlations with pharmacodynamic effects.

Condition Intervention Phase
Depressive Disorder, Treatment-Resistant
Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Resource links provided by NLM:

Further study details as provided by Avanir Pharmaceuticals:

Primary Outcome Measures:
  • Montgomery-Ǻsberg Depression Rating Scale (MADRS) total score [ Time Frame: Visit 5 (Day 70) Week 10 ]
    Montgomery-Ǻsberg Depression Rating Scale (MADRS) total score in patients receiving AVP 786 compared with patients administered placebo

Secondary Outcome Measures:
  • 17-item Hamilton Rating Scale for Depression (HAM-D17) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • 16-item Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • Sheehan Disability Scale (SDS) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • Clinical Global Impression of Severity of Illness (CGI-S) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • Clinical Global Impression of Change (CGI-C) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • EuroQOL 5 Dimension 5 Level (EQ-5D-5L) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • Patient Global Impression of Change (PGIC) [ Time Frame: Visit 5 (Day 70) Week 10 ]
  • 7-item Generalized Anxiety Disorder (GAD-7) [ Time Frame: Visit 5 (Day 70) Week 10 ]

Estimated Enrollment: 200
Study Start Date: July 2014
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AVP-786 Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
AVP-786 capsules administered twice a day over a 10-week period
Placebo Comparator: Placebo Drug: Placebo
Placebo capsules administered twice a day over a 10-week period

Detailed Description:

It is estimated that up to approximately 200 patients will participate in the study at approximately 30 enrolling centers in the US.

Eligible patients for this study must have MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria, and have shown an inadequate response to standard antidepressant treatment.

This is a multicenter, randomized, double-blind, placebo-controlled, study of 10 weeks duration.

Following screening procedures for assessment of inclusion and exclusion criteria, eligible patients will be randomized into the study. Study medication will be administered orally BID (1 capsule in the morning and 1 capsule in the evening, approximately 12 hours apart) throughout the treatment period.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of major depressive episode ≤ 24 months in duration
  • HAM-D17 score ≥ 20.
  • Documented to not have a significant (25% or greater) change in QIDS-SR16 score between Screening and Baseline visits.
  • Patients have been deemed to have an inadequate response (less than 50% symptom reduction) to at least 1 but no more than 3 adequate antidepressant trials during the current depressive episode.
  • Patients must be receiving ongoing treatment with an adequate dose of antidepressants.
  • Body Mass Index (BMI) of 18-35 kg/m².

Exclusion Criteria:

  • History of myasthenia gravis.
  • Have cardiovascular concerns such as:

    • History of complete heart block, QT interval corrected for heart rate (QTc) prolongation, or torsades de pointes.
    • QTc using the Fridericia's formula (QTcF) at screening > 450 msec for males and > 470 msec for females based on central review at the screening visit, unless due to ventricular pacing.
    • Any family history of congenital QT interval prolongation syndrome.
  • Known hypersensitivity/intolerance to DM, Q, opiate drugs (codeine, etc.), or any other ingredient of the study medication.
  • Pose a current suicide risk, as evidenced by any of the following:

    • It is the judgment of the investigator that the subject may be at risk for suicide.
    • The subject is rated a "yes" to question 4 or question 5 on the Baseline C-SSRS, if the most recent episode occurred within the past 12 months.
    • The subject has attempted suicide within the past 6 months
  • Presence of any other current DSM-IV-TR Axis I disorders with the exception of: generalized anxiety disorder (GAD: 300.02), social anxiety disorder (300.23), dysthymic disorder (300.4), or specific phobia (300.29). Patients with co-morbid GAD, social anxiety disorder, or specific phobia are ineligible if the co-morbid condition is clinically unstable, or has been the primary focus of treatment within the 6 month period prior to screening
  • Axis I diagnosis of:

    • Delirium, dementia, amnestic, or other cognitive disorder;
    • Schizophrenia or other psychotic disorder, based on the M.I.N.I.;
    • Bipolar I or II disorder, based on the M.I.N.I.
  • Clinically significant Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02153502

Contact: Long V Doan, MSPH 949-389-6767
Contact: Paul Shin 949-268-1174

  Show 32 Study Locations
Sponsors and Collaborators
Avanir Pharmaceuticals
  More Information

Responsible Party: Avanir Pharmaceuticals Identifier: NCT02153502     History of Changes
Other Study ID Numbers: 14-AVP-786-201
Study First Received: May 29, 2014
Last Updated: January 28, 2015

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Antidepressive Agents
Quinidine gluconate
Psychotropic Drugs
Antitussive Agents
Respiratory System Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Anti-Arrhythmia Agents
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors processed this record on April 25, 2017